DE69230372T2 - Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität - Google Patents

Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität

Info

Publication number
DE69230372T2
DE69230372T2 DE69230372T DE69230372T DE69230372T2 DE 69230372 T2 DE69230372 T2 DE 69230372T2 DE 69230372 T DE69230372 T DE 69230372T DE 69230372 T DE69230372 T DE 69230372T DE 69230372 T2 DE69230372 T2 DE 69230372T2
Authority
DE
Germany
Prior art keywords
biological activity
preparations
polyoxypropylen
polyoxyethylen
copolymere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230372T
Other languages
English (en)
Other versions
DE69230372D1 (de
Inventor
R Emanuele
Robert Hunter
Paula Culbreth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
CytRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69230372(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CytRx Corp filed Critical CytRx Corp
Publication of DE69230372D1 publication Critical patent/DE69230372D1/de
Application granted granted Critical
Publication of DE69230372T2 publication Critical patent/DE69230372T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
    • C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
    • C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
DE69230372T 1991-03-19 1992-03-18 Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität Expired - Fee Related DE69230372T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67328991A 1991-03-19 1991-03-19
US84787492A 1992-03-13 1992-03-13
PCT/US1992/002254 WO1992016484A1 (en) 1991-03-19 1992-03-18 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

Publications (2)

Publication Number Publication Date
DE69230372D1 DE69230372D1 (de) 2000-01-05
DE69230372T2 true DE69230372T2 (de) 2000-06-15

Family

ID=27100911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230372T Expired - Fee Related DE69230372T2 (de) 1991-03-19 1992-03-18 Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität

Country Status (19)

Country Link
US (7) US5523492A (de)
EP (1) EP0576612B1 (de)
JP (1) JP2647556B2 (de)
KR (1) KR100224539B1 (de)
CN (1) CN1069741A (de)
AT (1) ATE187154T1 (de)
AU (1) AU662146B2 (de)
CA (1) CA2106474C (de)
CZ (1) CZ194693A3 (de)
DE (1) DE69230372T2 (de)
DK (1) DK0576612T3 (de)
ES (1) ES2140408T3 (de)
GR (1) GR3032726T3 (de)
HU (1) HUT67762A (de)
IE (1) IE920860A1 (de)
IL (1) IL101305A (de)
NO (1) NO307890B1 (de)
SK (1) SK100893A3 (de)
WO (1) WO1992016484A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
DE69230372T2 (de) * 1991-03-19 2000-06-15 Cytrx Corp Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
CA2155005C (en) * 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
AU8076494A (en) * 1993-10-15 1995-05-04 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1998013069A2 (en) * 1996-09-09 1998-04-02 Supratek Pharma, Inc. Fluorinated copolymeric pharmaceutical adjuncts
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
AU1312800A (en) * 1998-10-09 2000-05-01 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
EP1183230A1 (de) * 1999-06-08 2002-03-06 La Jolla Pharmaceutical Valenz-plattformmoleküle mit aminooxygruppen
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
AU2001270147A1 (en) * 2000-06-23 2002-01-08 Merck & Co., Inc. Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
WO2002061040A2 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions
US6492881B2 (en) * 2001-01-31 2002-12-10 Compaq Information Technologies Group, L.P. Single to differential logic level interface for computer systems
NZ529526A (en) * 2001-04-24 2006-06-30 Purdue Research Foundation Method and compositions for treating mammalian nerve tissue injuries
EP1490090A4 (de) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
JP2005538191A (ja) * 2002-07-29 2005-12-15 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 水性２，６―ジイソプロピルフェノール医薬組成物
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
EP1578193A4 (de) * 2002-12-23 2011-06-15 Vical Inc Gefriertrocknungsverfahren für nukleinsäure-/blockcopolymer-/kationtensid-komplexe
EP1581201A4 (de) * 2002-12-23 2011-03-30 Vical Inc Verfahren zur herstellung steriler arzneimittel auf polynukleotidbasis
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
EP1605922A4 (de) 2003-03-24 2011-03-16 Biosphere Medical Inc Temporäre embolisation mit inversen thermosensiblen polymeren
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
MXPA06002470A (es) * 2003-09-05 2007-01-23 Ivy Animal Health Inc Copolimeros de polioxipropileno/polioxietileno purificados y metodo para preparar los mismos.
JP4898447B2 (ja) 2003-10-14 2012-03-14 プルーロームド インコーポレイテッド 結石破砕術の際の腎結石破片の閉じ込め
WO2005046438A2 (en) 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
JP4521547B2 (ja) * 2004-04-15 2010-08-11 株式会社サンメディカル技術研究所 血液ポンプの流量推定装置
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
CA2599219C (en) * 2005-02-25 2011-09-20 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
SI1877096T1 (sl) 2005-05-02 2014-08-29 Genzyme Corporation Terapija ledvičnih kamnov brez litotripsije
US8815557B2 (en) * 2005-07-08 2014-08-26 University Of Chicago Compositions and methods for refolding of denatured proteins
US20080031847A1 (en) * 2005-12-22 2008-02-07 Pluromed, Inc. Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers
CN103271935A (zh) * 2006-08-01 2013-09-04 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
JP5513115B2 (ja) 2006-09-11 2014-06-04 プルーロームド インコーポレイテッド 非外傷性閉塞バルーン及びスカート並びにその使用方法
CN101677822A (zh) * 2006-12-11 2010-03-24 普拉罗美德公司 灌注器官止血法
BRPI0807558A2 (pt) * 2007-02-22 2014-07-01 Pluromed Inc Uso de polímeros termosensíveis reversos para controlar o fluxo de fluido biológico subsequente a um procedimento médico
MX2009010778A (es) * 2007-04-05 2010-01-29 Phrixus Pharmaceuticals Inc Composiciones y metodos para el tratamiento de insuficiencia cardiaca.
AU2008287419A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
EP2219546B1 (de) * 2007-11-29 2017-02-01 Genzyme Corporation Endoskopische schleimhaut-resektionierung mit gereinigten inversen wärmeempfindlichen polymeren
EP2719389B1 (de) 2007-12-17 2016-07-06 The Regents Of The University Of Michigan Zusammensetzungen und Verfahren zur Behandlung und Vorbeugung von Skelettmuskelmängeln
CA2744100C (en) 2008-10-21 2020-06-30 The General Hospital Corporation Cell transplantation
DE102008043343A1 (de) * 2008-10-31 2010-05-06 Evonik Goldschmidt Gmbh Silikonpolyetherblock-Copolymere mit definierter Polydispersität im Polyoxyalkylenteil und deren Verwendung als Stabilisatoren zur Herstellung von Polyurethanschäumen
WO2010072769A1 (de) 2008-12-23 2010-07-01 Basf Se Verfahren zur herstellung von polyether-blockcopolymeren
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
GB201008902D0 (en) * 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
BR112013002859B1 (pt) 2010-08-06 2020-10-06 The General Hospital Corporation D/B/A Massachusetts General Hospital Método e aparelho para tratamento de células
WO2012068079A1 (en) 2010-11-15 2012-05-24 Adventrx Pharmaceuticals, Inc. Methods for enhancing oxygenation of jeopardized tissue
CN103732233B (zh) 2011-03-18 2016-08-10 贝克斯特国际公司 包含葡萄糖聚合物的腹膜透析溶液
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
US9662345B2 (en) 2013-06-14 2017-05-30 Professional Compounding Centers Of America Antibiotic composition for inhalation and irrigation
KR20160073391A (ko) 2013-10-16 2016-06-24 매스트 테라퓨틱스 인코포레이티드 이뇨제 유도된 혈장량의 변화
JP6202471B2 (ja) 2013-10-31 2017-09-27 日油株式会社 医用ポリオキシプロピレン重合体の製造方法および医用ポリオキシプロピレン／ポリオキシエチレンブロック共重合体の製造方法
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US9403941B2 (en) 2014-07-07 2016-08-02 Mast Therapeutics, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof
US20160000823A1 (en) * 2014-07-07 2016-01-07 Mast Therapeutics, Inc. Methods and compositions for improving hemostasis
WO2017108457A1 (en) 2015-12-22 2017-06-29 Basf Se A process for purification of polyether block copolymers
JP2020506276A (ja) * 2017-02-09 2020-02-27 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリエーテルブロックコポリマーの精製方法
WO2019125783A1 (en) * 2017-12-21 2019-06-27 Sigma-Aldrich Co. Llc Poloxamer compositions and methods of making and using same
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2979528A (en) * 1953-10-19 1961-04-11 Wyandotte Chemicals Corp Nitrogen-containing polyoxyalkylene detergent compositions
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US3022335A (en) * 1955-03-30 1962-02-20 Wyandotte Chemicals Corp Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains
US2854378A (en) * 1955-12-08 1958-09-30 Bristol Lab Inc Tetracycline suppository
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3228834A (en) * 1962-06-08 1966-01-11 Hoffmann La Roche Pharmaceutical diluent compositions
US3140232A (en) * 1962-12-19 1964-07-07 Pfizer & Co C Color stabilization of tetracycline compositions with polypropylene glycols
US3391196A (en) * 1965-08-16 1968-07-02 Wyandotte Chemicals Corp High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4104455A (en) * 1975-03-25 1978-08-01 Toyo Soda Manufacturing Co., Ltd. Polymerization of monomer
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4195167A (en) 1976-05-28 1980-03-25 Union Carbide Corporation Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same
JPS545094A (en) 1977-06-09 1979-01-16 Tokyo Tanabe Co Production of pharmaceutical urokinase from contamination free human urine
DE2732929A1 (de) * 1977-07-21 1979-02-01 Bayer Ag Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
DE2961374D1 (en) * 1978-01-27 1982-01-28 Bp Chem Int Ltd A method for increasing the selectivity to acetic acid in the production of a mixture of c1 to c3 monocarboxylic acids by oxidation of paraffinic hydrocarbons
DE2808865A1 (de) * 1978-03-02 1979-09-13 Hoechst Ag Mikrobiozide mittel auf der basis von alkyl-di-guanidinium-salzen
US4275244A (en) * 1978-05-11 1981-06-23 Basf Wyandotte Corporation Linear polyalkylene ether glycols of high molecular weight
JPS5533194A (en) 1978-08-07 1980-03-08 Scholz D Thomas Stringgfastener device including tremolant
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE2850058A1 (de) * 1978-11-18 1980-05-29 Bayer Ag Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2454409A1 (fr) * 1979-04-18 1980-11-14 Sovam Vehicule tracteur notamment pour avions gros porteurs
FI803077A (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
US4575484A (en) * 1980-05-05 1986-03-11 Montefiore Medical Center, Inc. Binding assay for the detection of mycobacteria
US4410660A (en) * 1980-05-05 1983-10-18 Montefiore Medical Center Binding assay for the detection of mycobacteria
US4489158A (en) * 1980-05-05 1984-12-18 Montefiore Hospital And Medical Center, Inc. Binding assay for the detection of mycobacteria
JPS578223A (en) * 1980-06-19 1982-01-16 Mitsui Petrochem Ind Ltd Production of alkylene oxide block copolymer
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
GR78246B (de) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US4407790A (en) * 1981-09-25 1983-10-04 Economics Laboratory, Inc. Method of controlling bloat using nonionic surfactants
EP0098110B1 (de) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Zusammensetzung mit längerer Wirkung
DE3234084A1 (de) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
SU1183112A1 (ru) * 1983-08-04 1985-10-07 Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср Способ лечени острой ишемии миокарда
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
ATE142502T1 (de) * 1986-05-15 1996-09-15 Univ Emory Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
JP2527942B2 (ja) * 1986-09-18 1996-08-28 ティーディーケイ株式会社 磁気記録媒体
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) * 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
ATE82129T1 (de) * 1987-02-20 1992-11-15 Univ Emory Antiinfektioese verbindungen und verfahren zur verwendung.
US5811088A (en) 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
JPH07109520B2 (ja) 1987-02-24 1995-11-22 株式会社リコー 電子写真用感光体
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE4014923A1 (de) * 1990-05-10 1991-11-14 Basf Ag Verfahren zur herstellung von urethan- oder urethan- und isocyanuratgruppen enthaltenden hartschaumstoffen nach dem polyisocyanat-polyadditionsverfahren und die hierfuer geeigneten polyoxyalkylen-polyole
DE69230372T2 (de) * 1991-03-19 2000-06-15 Cytrx Corp Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides

Also Published As

Publication number Publication date
US5523492A (en) 1996-06-04
DE69230372D1 (de) 2000-01-05
ES2140408T3 (es) 2000-03-01
DK0576612T3 (da) 2000-05-22
CA2106474C (en) 2004-02-10
KR100224539B1 (ko) 1999-10-15
JP2647556B2 (ja) 1997-08-27
HUT67762A (en) 1995-04-28
NO933337D0 (no) 1993-09-17
US5990241A (en) 1999-11-23
NO307890B1 (no) 2000-06-13
EP0576612B1 (de) 1999-12-01
IL101305A (en) 1995-11-27
EP0576612A1 (de) 1994-01-05
HU9302628D0 (en) 1993-12-28
WO1992016484A1 (en) 1992-10-01
NO933337L (no) 1993-11-17
US5691387A (en) 1997-11-25
IE920860A1 (en) 1992-09-23
JPH06506258A (ja) 1994-07-14
GR3032726T3 (en) 2000-06-30
AU662146B2 (en) 1995-08-24
US6747064B2 (en) 2004-06-08
IL101305A0 (en) 1992-11-15
USRE36665E (en) 2000-04-18
US20020183398A1 (en) 2002-12-05
USRE37285E1 (en) 2001-07-17
ATE187154T1 (de) 1999-12-15
EP0576612A4 (de) 1994-11-09
CN1069741A (zh) 1993-03-10
US6359014B1 (en) 2002-03-19
SK100893A3 (en) 1994-04-06
CA2106474A1 (en) 1992-09-20
AU1773092A (en) 1992-10-21
CZ194693A3 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
ATE187154T1 (de) Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
DE69024965D1 (de) Dehydrodidemnin b
DK0611522T3 (da) Synergistiske mikrobicide sammensætninger
ATE189263T1 (de) Auswahl von effizient ziel-rns spaltenden ribozymen
PL308122A1 (en) Viral vectors and their application in genic therapy
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DK480284A (da) Sporstofmaerkede konjugater af metallothionein og maalsoegende, biologisk aktive molekyler
TR28384A (tr) Flüoroalifatik -ve karboksil- iceren terminal gruplarina sahip polisilokzanlar, bunlarin hazirlanmasi, ve lifli malzemelerin muamelesinde kullanimlari.
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE3884453D1 (de) Homogene additionscopolymere von ethylen und cycloolefinmonomeren und deren herstellung.
ATE208208T1 (de) Halogenid-enthaltende insulinzubereitungen
EP0671934A4 (de) Verfahren zur Behandlung von Zellschaden und Depletion.
SE9101815D0 (sv) Behandling av sjukdom foerbunden med hiv-infektioner
DK0445781T3 (da) Anti-glaucomapræparater indeholdende 3-arylcarbonyl-1-aminoalkyl-1H-indol
ITMI912456A0 (it) Ossa(tia)diazol- e triazol-oni(tioni)ad attivita' acarcida ed insetticida
RS49520B (sr) Antimikrobno aktivne smeše
MY107501A (en) Continuously magnetizing magnet.
ES2013025A6 (es) Un metodo para preparar 24r-escimnol.
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ES2077614T3 (es) Bacillus thuringiensis, variedad donegani, y preparacion o toxina obtenida de esta, dotado de actividad insecticida frente a cleopteros.
FR2370053A1 (fr) Acides 7-acylamino-3-(1-(2,3-dihydroxypropyl)tetrazole-5-ylthiomethyl)-3-cepheme-4-carboxyliques et leur application en therapeutique
RU93056161A (ru) Блок-сополимер полиоксипропилена и полиоксиэтилена, поверхностно-активный сополимер, способ получения нетоксичного поверхностно-активного сополимера, лекарственное средство
BE905706A (fr) Melanges herbicides et leur utilisation pour le traitement des cultures.
Cyr Self-disclosure by marital therapists and consequent spouse responses.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee